Drugs / P-CD19CD20-ALLO1 Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06984341 | Jun 2026 → Nov 2033 expected | systemic lupus erythematosus | Genentech, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-CD19CD20-ALLO1 Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06984341 ↗ |
| Modality | Cell therapy | “Biological: P-CD19CD20-ALLO1 Cells” NCT06984341 ↗ |
| Route | Intravenous | “P-CD19CD20-ALLO1 cells will be administered intravenously as per the schedule specified in the protocol.” NCT06984341 ↗ |